Fig. 3From: Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension studyRelapse outcomes presented as a aggregate annualized relapse rate up to end of study by time period and treatment, and b Kaplan-Meier plot of time to first confirmed relapseBack to article page